The following is a summary of “Risks of adverse events with mirtazapine for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis,” published in the January 2025 issue of Psychiatry by Kamp et al.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of interest in everyday activities, appetite changes, sleep disturbances and, in extreme cases,

I’ve been living with depression for almost 12 years. I’m 31 now and I found out I had major depressive disorder when I was 19. I had a miserable freshman year of college, but I didn't really ...

When you have major depressive disorder (MDD), understanding what to expect can help you manage the ups and downs. When someone I work with is newly diagnosed, I spend a lot of time educating them ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in depression in those of European and non-European ancestry.

Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of major depressive disorder (MDD),

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Neurocrine Biosciences begins phase 3 registrational study of osavampator as an adjunctive therapy to treat major depressive disorder: San Diego Wednesday, January 29, 2025, 18:00

People with bipolar I disorder have had at least one manic episode preceded or followed by hypomanic or major depressive episodes.

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.